AGM Statement

Sareum Holdings PLC
15 November 2007


For immediate release                                           15 November 2007                                  


                              SAREUM HOLDINGS PLC
                          ("Sareum" or "the Company")

                                 AGM Statement


At the Company's annual general meeting held today, the following resolutions
were passed unanimously by shareholders on a show of hands.


The proxy votes received prior to the meeting on each resolution were as
follows:

ORDINARY RESOLUTIONS                     Votes    Discretion     Votes     Votes
                                          For                   Against   Withheld

1.To receive and adopt the
Directors' report
and financial statements for the year  8,724,070    221,058         0        0
ended 30 June 2007.                        97.53%      2.47%        0%       0%


2. To receive and adopt the
Remuneration
Committee report for the year ended    8,679,070    266,058         0        0
30 June 2007.                               7.03%      2.97%        0%       0%
                                     

3.To re-elect Dr Paul Harper  8,724,070    221,058         0        0
as Director.                      97.53%      2.47%        0%       0%
 
                           
4.To re-elect Mr Giorgio
Reggiani as                            8,576,070    366,058     3,000        0
Director.                                  95.88%      4.09%     0.03%       0%


5.To re-appoint Shipleys LLP
as auditors and
authorise the Directors to fix their   8,721,070    221,058     3,000        0
remuneration.                              97.50%      2.47%     0.03%       0%

6.To authorise Directors for the
purposes of
section 80 of the Companies Act 1985
(the
Act) to allot relevant securities      
(within                                8,531,070    366,058    48,000        0
the meaning of that section) up to an      95.37%      4.09%     0.54%       0%
aggregate nominal amount of £90,000.



SPECIAL RESOLUTIONS                  Votes        Discretion Votes      Votes
                                     For                     Against    Withheld
7.Subject to the passing of resolution
6, to
authorise Directors, in accordance
with
section 95 of the Act, to allot
equity                                
securities (as defined in section 94      
of
the Act) wholly for cash up to an     8,531,070    321,058     93,000        0
aggregate nominal amount of £50,000.      95.37%      3.59%      1.04%       0%

                                          
8.To authorise the Company to send or
supply
documents or information to
shareholders                          
by making them available on the       8,549,070    266,058    130,000        0
Company's                                 95.58%      2.97%      1.45%       0%
website or other electronic means.

For further information please contact:

Sareum Holdings                                             [phone]                         

Tim Mitchell, Chief Executive Officer

Buchanan Communications                                     [phone]
                                                                            

Tim Anderson, Mary-Jane Johnson

Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs
for the treatment of cancer and to provide a range of drug discovery services to
the pharmaceutical industry. Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.


A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease. Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression. Knowledge of the
structure of the potential drugs and how they 'lock-in' to the protein permits
the best potential drug to be discovered. Determining structure is a complex
task and requires leading-edge equipment and experienced staff. Sareum's
approach to structure determination is to produce multiple recombinant proteins
primarily through a baculovirus expression system and to determine their
structure using x-ray crystallography.


When the structure is determined, the Company's innovative Template Screening
platform is used to identify novel chemical starting material designed to
interact with the target protein. Sareum then uses its high-throughput medicinal
chemistry platform to rapidly optimise these molecules and develop the most
promising into potential drug candidates.


Sareum provides its specialist drug discovery capabilities to partners in the
pharmaceutical and biotechnology industries. The Company aims to successfully
deliver: Programmes for complete gene-to-candidate structure-based discovery;
projects to accelerate or improve the productivity of specific activities; and
drug candidates for licensing at the Phase I or Phase II clinical trials stage.


Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange